The Solubility–Permeability Interplay and Its Implications in Formulation Design and Development for Poorly Soluble Drugs
Journal Title: The AAPS Journal - Year 2012, Vol 14, Issue 2
Abstract
While each of the two key parameters of oral drug absorption, the solubility and the permeability, has been comprehensively studied separately, the relationship and interplay between the two have been largely ignored. For instance, when formulating a low-solubility drug using various solubilization techniques: what are we doing to the apparent permeability when we increase the solubility? Permeability is equal to the drug’s diffusion coefficient through the membrane times the membrane/aqueous partition coefficient divided by the membrane thickness. The direct correlation between the intestinal permeability and the membrane/aqueous partitioning, which in turn is dependent on the drug’s apparent solubility in the GI milieu, suggests that the solubility and the permeability are closely associated, exhibiting a certain interplay between them, and the current view of treating the one irrespectively of the other may not be sufficient. In this paper, we describe the research that has been done thus far, and present new data, to shed light on this solubility–permeability interplay. It has been shown that decreased apparent permeability accompanies the solubility increase when using different solubilization methods. Overall, the weight of the evidence indicates that the solubility–permeability interplay cannot be ignored when using solubility-enabling formulations; looking solely at the solubility enhancement that the formulation enables may be misleading with regards to predicting the resulting absorption, and hence, the solubility–permeability interplay must be taken into account to strike the optimal solubility–permeability balance, in order to maximize the overall absorption.
Authors and Affiliations
Arik Dahan, Jonathan M. Miller
Keywords
Related Articles
- EP ID EP681208
- DOI 10.1208/s12248-012-9337-6
- Views 167
- Downloads 0
Development of a GC-MS Assay for the Determination of Fentanyl Pharmacokinetics in Rabbit Plasma after Sublingual Spray Delivery
Fentanyl free base was kindly supplied by Insys Therapeutics, Inc (Mundelein, IL), fentanyl citrate and sufentanil free base were obtained from Mallinckrodt Chemicals (St. Louis, MO). 1-Chlorobutane was purchased from Ac...
Regulatory Administrative Databases in FDA's Center for Biologics Evaluation and Research: Convergence Toward a Unified Database
Regulatory administrative database systems within the Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) are essential to supporting its core mission, as a regulatory agency. Such sy...
Particle size analysis of concentrated phospholipid microemulsions: II. Photon correlation spectroscopy
The solvated droplet size of concentrated water-in-oil (w/o) microemulsions prepared frome egg and soy lecithin/water/isopropyl myristate and containing short-chain alcohol cosurfactants has been determined using photon...
Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse
The discovery and preclinical development of selective dopamine reuptake inhibitors as potential pharmacotherapies for treating cocaine addiction are presented. The studies are based on the hypothesis that a dopamine reu...
A Platform for Characterizing Therapeutic Monoclonal Antibody Breakdown Products by 2D Chromatography and Top-Down Mass Spectrometry
The online version of this article (doi:10.1208/s12248-012-9361-6) contains supplementary material, which is available to authorized users.